[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmnary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmnary-hypertension":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100603446","detecting-pulmonary-hypertension-with-the-eko-core-500-digital-stethoscope-100603446",false,"NCT07136623","Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope","Deep Learning for Algorithmic Detection of Pulmonary Hypertension Using a Combined Digital Stethoscope and Three-lead Electrocardiogram","EKO-PH","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nAble and willing to provide informed consent.\n\nClinically indicated transthoracic echocardiogram (TTE) or right heart catheterization (RHC) scheduled\u002Fperformed within ±7 days of the study recording visit.\n\nExclusion Criteria:\n\nUnwilling or unable to provide informed consent.\n\nCurrently hospitalized at the time of study procedures.\n\nIf enrolled via TTE path: limited (non-diagnostic) echocardiogram.",true,"ALL","18 Years",{"count":21,"type":22},1513,"ESTIMATED","OBSERVATIONAL","This prospective, observational study will evaluate whether synchronized heart sound (phonocardiogram, PCG) and three-lead electrocardiogram (ECG) recordings (entered as separate interventions in PRS, though collected together in practice) collected with the Eko CORE 500 can help screen for pulmonary hypertension (PH). Adults (≥18 years) undergoing clinically indicated transthoracic echocardiography (TTE) and\u002For right heart catheterization (RHC) will complete one study visit (\\~20 minutes). During the visit, study staff will obtain at least four 15-second CORE 500 recordings (aortic, pulmonic, tricuspid, and mitral areas). The clinical echocardiogram (and RHC, if performed) within ±7 days of the recordings will provide reference labels for the presence and severity of PH; de-identified demographic and clinical data may also be abstracted from the medical record.\n\nThe primary objective is to develop and validate a software algorithm to detect PH and, where possible, stratify severity using noninvasive PCG+ECG signals. These recordings are investigational data acquisitions for algorithm development only; they are not diagnostic procedures and will not be used for clinical decision-making. Primary performance measures are sensitivity and specificity versus echocardiogram and RHC references. No clinical decisions will be based on the investigational algorithm, and no changes to standard care are required. The study plans to enroll up to \\~1,513 participants to obtain approximately 1,375 evaluable datasets across multiple outpatient sites.",[26],"Pulmnary Hypertension",[28],"pulmonary hypertension","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2025-08-01",{"date":37,"type":22},"2027-05-31",{"name":39,"class":40},"Eko Devices, Inc.","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100613236","hemodynamic-effects-of-inhaled-iloprost-in-ph-copd-hollywood-100613236","NCT07263958","Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)","HOLLYWOOD: Hemodynamic Evaluation and Management of Pulmonary Hypertension With Inhaled Iloprost in Chronic Obstructive Pulmonary Disease","HOLLYWOOD","Inclusion Criteria:\n\n* Age 40 years or older.\n* Established diagnosis of severe or very severe Chronic Obstructive Pulmonary Disease (COPD), corresponding to GOLD stage 3 or 4.\n* Symptomatic Group 3 Pulmonary Hypertension (PH) confirmed by Right Heart Catheterization (RHC) with the following hemodynamic profile at rest:\n* Mean Pulmonary Artery Pressure (mPAP) \\> 35 mmHg.\n* Pulmonary Vascular Resistance (PVR) \\> 5 Wood Units (WU).\n* Pulmonary Capillary Wedge Pressure (PCWP) ≤ 15 mmHg.\n* Capable of providing written informed consent.\n\nExclusion criteria:\n\n* History of hypersensitivity to iloprost or other prostacyclin analogs.\n* Pregnancy or breastfeeding.","40 Years",{"count":51,"type":22},15,"INTERVENTIONAL",[54],"NA","Study Title: A Clinical Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension in Patients With Chronic Obstructive Pulmonary Disease (HOLLYWOOD)\n\nThe goal of this clinical study is to learn if the inhaled drug iloprost is effective and safe for treating pulmonary hypertension (PH) in adult patients who have severe or very severe Chronic Obstructive Pulmonary Disease (COPD).\n\nThe main questions it aims to answer are:\n\nDoes inhaled iloprost reduce the pressure and resistance in the lung's blood vessels (measured as Pulmonary Vascular Resistance - PVR)?\n\nDoes inhaled iloprost improve participants' ability to exercise, measured by how far they can walk in 6 minutes?\n\nWhat are the side effects and medical problems that participants experience while taking inhaled iloprost?\n\nResearchers will assess changes in participants' health by comparing measurements taken before they start taking inhaled iloprost to measurements taken after 12 weeks of treatment. There is no placebo group in this study.\n\nParticipants in this study will:\n\nUse an inhaler to take iloprost 6 to 9 times every day for 12 weeks.\n\nVisit the clinic for checkups at the beginning of the study and after the 12-week treatment period.\n\nUndergo tests including an exercise capacity test (the 6-minute walk test) and heart pressure measurements (hemodynamic tests) before and after the treatment period.",[26,57,58],"COPD","Pulmonary Hypertension Secondary to Lung Disease and\u002For Hypoxia",[60,57,61,62,63,64,65,66],"Pulmonary Hypertension","Hemodynamics","Prostacyclin Analog","iloprost","Chronic Obstructive Pulmonary Disease (COPD)","Group 3 Pulmonary Hypertension","PH-COPD","NOT_YET_RECRUITING","2025-11-23",{"date":70,"type":33},"2025-12-04",{"date":72,"type":22},"2025-12-10",{"date":74,"type":22},"2026-12-20",{"name":76,"class":77},"University of Sao Paulo General Hospital","OTHER"]